| 1. |
- Döring, J., et al.
(författare)
-
Band terminations in the valence space of 86Zr
- 2000
-
Ingår i: Physical Review C - Nuclear Physics. - 0556-2813. ; 61:3, s. 343101-343106
-
Tidskriftsartikel (refereegranskat)abstract
- High-spin states in 86Zr up to 30+ and 27- were observed via the 58Ni(32S,4p) reaction at 135 MeV beam energy using the combined GAMMASPHERE and MICROBALL systems. Calculations performed with the configuration-dependent shell-correction approach show that these states are built from six g9/2 neutrons and at most four protons excited from the p1/2,p3/2,f5/2 subshells to the g9/2 subshell at small deformation. The highest observed states at 27- and 30+ are interpreted as band-terminating states with the latter having the highest spin available in the valence space for 86Zr.
|
|
| 2. |
- Solomon, S. D., et al.
(författare)
-
Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program
- 2004
-
Ingår i: Circulation. - 1524-4539. ; 110:15, s. 2180-3
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Patients with heart failure are at increased risk of sudden death and death attributed to progressive pump failure. We assessed the effect of candesartan on cause-specific mortality in patients enrolled in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. METHODS AND RESULTS: The CHARM program consisted of 3 component trials that enrolled patients with symptomatic heart failure: CHARM-Alternative (n=2028; LVEF<=40% [corrected] and ACE intolerant), CHARM-Added (n=2548; LVEF<=40%, [corrected] already on ACE inhibitors), and CHARM-Preserved (n=3023; LVEF >40%). Patients were randomized to candesartan, titrated to 32 mg QD, or placebo and were followed up for a median of 37.7 months. All deaths were reviewed by a blinded adjudication committee and categorized according to prespecified definitions on the basis of a narrative and source documentation. The number and rate of deaths by cause were calculated for each of the component trials and the overall program. Of all the patients, 8.5% died suddenly, and 6.2% died of progressive heart failure. Candesartan reduced both sudden death (HR 0.85 [0.73 to 0.99], P=0.036) and death from worsening heart failure (HR 0.78 [0.65 to 0.94], P=0.008). These reductions were most apparent in the patients with LVEF<=40% [corrected]. CONCLUSIONS: Candesartan reduced sudden death and death from worsening heart failure in patients with symptomatic heart failure, although this reduction was most apparent in patients with systolic dysfunction.
|
|
| 3. |
- Young, J. B., et al.
(författare)
-
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials
- 2004
-
Ingår i: Circulation. - 1524-4539. ; 110:17, s. 2618-26
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Patients with symptomatic chronic heart failure (CHF) and reduced left ventricular ejection fraction (LVEF) have a high risk of death and hospitalization for CHF deterioration despite therapies with angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and even an aldosterone antagonist. To determine whether the angiotensin-receptor blocker (ARB) candesartan decreases cardiovascular mortality, morbidity, and all-cause mortality in patients with CHF and depressed LVEF, a prespecified analysis of the combined Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) low LVEF trials was performed. CHARM is a randomized, double-blind, placebo-controlled, multicenter, international trial program. METHODS AND RESULTS: New York Heart Association (NYHA) class II through IV CHF patients with an LVEF of < or =40% were randomized to candesartan or placebo in 2 complementary parallel trials (CHARM-Alternative, for patients who cannot tolerate ACE inhibitors, and CHARM-Added, for patients who were receiving ACE inhibitors). Mortality and morbidity were determined in 4576 low LVEF patients (2289 candesartan and 2287 placebo), titrated as tolerated to a target dose of 32 mg once daily, and observed for 2 to 4 years (median, 40 months). The primary outcome (time to first event by intention to treat) was cardiovascular death or CHF hospitalization for each trial, with all-cause mortality a secondary end point in the pooled analysis of the low LVEF trials. Of the patients in the candesartan group, 817 (35.7%) experienced cardiovascular death or a CHF hospitalization as compared with 944 (41.3%) in the placebo group (HR 0.82; 95% CI 0.74 to 0.90; P<0.001) with reduced risk for both cardiovascular deaths (521 [22.8%] versus 599 [26.2%]; HR 0.84 [95% CI 0.75 to 0.95]; P=0.005) and CHF hospitalizations (516 [22.5%] versus 642 [28.1%]; HR 0.76 [95% CI 0.68 to 0.85]; P<0.001). It is important to note that all-cause mortality also was significantly reduced by candesartan (642 [28.0%] versus 708 [31.0%]; HR 0.88 [95% CI 0.79 to 0.98]; P=0.018). No significant heterogeneity for the beneficial effects of candesartan was found across prespecified and subsequently identified subgroups including treatment with ACE inhibitors, beta-blockers, an aldosterone antagonist, or their combinations. The study drug was discontinued because of adverse effects by 23.1% of patients in the candesartan group and 18.8% in the placebo group; the reasons included increased creatinine (7.1% versus 3.5%), hypotension (4.2% versus 2.1%), and hyperkalemia (2.8% versus 0.5%), respectively (all P<0.001). CONCLUSIONS: Candesartan significantly reduces all-cause mortality, cardiovascular death, and heart failure hospitalizations in patients with CHF and LVEF < or =40% when added to standard therapies including ACE inhibitors, beta-blockers, and an aldosterone antagonist. Routine monitoring of blood pressure, serum creatinine, and serum potassium is warranted.
|
|
| 4. |
- Cardona, R., et al.
(författare)
-
High-spin structure of normal-deformed bands in 84Zr
- 2003
-
Ingår i: Physical Review C - Nuclear Physics. - 0556-2813. ; 68, s. 1-024303
-
Tidskriftsartikel (refereegranskat)abstract
- The reaction 58Ni(32S, α2p) at E lab= 135 MeV was used to populate high-spin states in 84Zr. The complete GAMMASPHERE and MICROBALL arrays were used to obtain clean γ- γ- γ line shapes to be analyzed by the Doppler shift attenuation method and to determine 27 lifetimes in the ground-state band and in two excited bands. Side-feeding times were also measured by comparing the line shapes gated with transitions above and below the state under study. The deduced electric quadrupole moments for the ground-state band are consistent with a very slow reduction with frequency with values ranging between 2.4(3) and 2.0(1)e b. The negative-parity bands feature also an approximate constancy of quadrupole moment with values similar to those in the ground-state band. Cranking calculations agree with this behavior in both parity bands and suggest an interpretation of the upper states in the ground-state band as part of a very slowly terminating band. Shell-dependent cranked Nilsson calculations explain a fourth γ cascade as pertaining to a noncollective structure terminating at I = 20+.
|
|
| 5. |
- Wiedeking, M., et al.
(författare)
-
Transition strengths and band terminations in 86Zr
- 2003
-
Ingår i: Physical Review C - Nuclear Physics. - 0556-2813. ; 67, s. 1-034320
-
Tidskriftsartikel (refereegranskat)abstract
- High angular momentum states in 86Zr were populated through the 58Ni(32S,4p) reaction at 135 MeV using the 88-In. Cyclotron at Lawrence Berkeley National Laboratory. Recoiling 86Zr nuclei were stopped in a thick Ta backing. Prompt multi-γ coincidences with evaporated charged particles were detected using the full array of GAMMASPHERE and the MICROBALL. Mean lifetimes of 36 levels in 86Zr were measured using the Doppler-shift attenuation method. Transition quadrupole moments Qt were found in the range of about 0.3-1.5 e b in the positive-parity bands. The negative-parity bands show Qt values from about 0.25 to 1.2 e b. In the yrast positive-parity band, a sharp drop in collectivity approaching the 30+ state supports the interpretation of band termination in this configuration. Decreasing Qt values approaching the 24+ and 27- states also provide an indication of terminating structures.
|
|
